Peptide News Digest

#Klra

2 stories

Industry · View digest

Kailera Therapeutics (NASDAQ: KLRA) Received Sweeping Positive Analyst Coverage Following Its August 12 Q2 2026 Earnings Report Confirming an Active Investigational New Drug (IND) Application With the FDA for Ribupatide Oral (KAI-9531-T) and Global Phase 3 Obesity Trials Planned for H1 2027, With 6 Analysts Averaging a Strong Buy Rating and a $42.60 12-Month Price Target (Representing 82.83% Upside From the $17.95-$19.50 Trading Range on August 13-14), Including TD Cowen at Buy With a $57 Price Target, Evercore ISI at Outperform, and William Blair at Outperform; The Company Holds Cash, Cash Equivalents, and Marketable Securities Expected to Support Execution of Multiple Clinical Milestones With Runway Into Mid-2028; Ribupatide Is a Once-Weekly GLP-1/GIP Dual Agonist Peptide That Reached 23.6% Mean Weight Loss at 8 mg Over 36 Weeks in Phase 2 Injection Trial, With the Oral Formulation Reaching Up to 12.1% Weight Loss and 38.6% of Participants Achieving ≥15% Loss in Hengrui's Phase 2 Trial

Kailera Therapeutics (NASDAQ: KLRA) received sweeping positive analyst coverage following its August 12, 2026 Q2 2026 earnings report. Kailera confirmed an active Investigational New Drug (IND) application with the FDA for ribupatide oral (KAI-9531-T) and global Phase 3 obesity trials planned for H1 2027. Analyst response: according to 6 analysts, the average rating for KLRA stock is Strong Buy, with a 12-month average price target of $42.60 representing 82.83% upside from the $17.95-$19.50 trading range on August 13-14. Named ratings include TD Cowen at Buy with a $57 price target, Evercore ISI at Outperform, and William Blair at Outperform. The company holds cash, cash equivalents, and marketable securities expected to support execution of multiple clinical milestones with runway into mid-2028. Ribupatide mechanism: a once-weekly GLP-1/GIP dual agonist peptide (mechanistically similar to Eli Lilly's tirzepatide) with the ribupatide injection Phase 2 trial reaching 23.6% mean weight loss at 8 mg over 36 weeks, and the oral formulation reaching up to 12.1% weight loss with 38.6% of participants achieving at least 15% loss at Week 26 in Hengrui's Phase 2 trial. The Phase 2b high-dose injection trial in obesity is fully enrolled with data anticipated in mid-2027.

Clinical Trials · View digest

Kailera Therapeutics (NASDAQ: KLRA) Reported August 12 Q2 2026 Financial Results and Disclosed an Active Investigational New Drug (IND) Application With the US FDA for Ribupatide Oral (KAI-9531-T), a Triple Agonist (GLP-1/GIP/Glucagon) Peptide for Obesity Being Co-Developed With Hengrui Pharma, With Global Phase 3 Obesity Trials Planned to Initiate in H1 2027 Following Hengrui's Phase 2 Trial in Adults With Obesity That Documented Up to 12.1% Mean Weight Loss With No Observed Plateau at Week 26 and Up to 38.6% of Participants Achieving at Least 15% Weight Loss at the 25 mg and 50 mg Once-Daily Oral Doses; A Ribupatide Injection Phase 2b High-Dose Trial in Obesity Is Fully Enrolled With Data Anticipated in Mid-2027

Kailera Therapeutics (NASDAQ: KLRA) reported August 12, 2026 Q2 2026 financial results and disclosed an active Investigational New Drug (IND) application with the US FDA for ribupatide oral (KAI-9531-T), a triple agonist (GLP-1, GIP, and glucagon receptor) peptide for obesity being co-developed with Hengrui Pharma. Global Phase 3 obesity trials are planned to initiate in H1 2027. Phase 2 data foundation: Hengrui's Phase 2 trial in adults with obesity documented up to 12.1% mean weight loss with no observed plateau at Week 26 and up to 38.6% of participants achieving at least 15% weight loss at the 25 mg and 50 mg once-daily oral doses. A ribupatide injection Phase 2b high-dose trial in obesity is fully enrolled with data anticipated in mid-2027. Ribupatide competes mechanistically with Eli Lilly's retatrutide (once-weekly injectable triple agonist, roughly 28.7% weight loss at 68 weeks in Phase 3 TRIUMPH-4) in the triple-agonist class. The oral formulation could compete with Lilly's orforglipron (oral small-molecule GLP-1 agonist, roughly 7.5-11.2% weight loss over 72 weeks) and Novo Nordisk's Wegovy pill (oral semaglutide 25/50 mg). Kailera holds US and ex-China commercial rights via a license from Hengrui.